Financial Report: Amgen

Amgen

2Q Revenues: $4.7 billion (+5%)

2Q Earnings: $1.3 billion (-1%)

YTD Revenues: $8.7 billion (+8%)

YTD Earnings: $2.7 billion (+10%)

Comments: Combined Neulasta and Neupogen sales increased 7% to $1.4 billion in the quarter. Enbrel sales increased 9% to $1.2 billion. Sensipar/Mimpara sales increased 12% to $259 million. XGEVA sales increased 39% to $249 million and Prolia sales increased 57% to $188 million. Aranesp sales decreased 2% to $524 million and Epogen sales were down 4% to $502 million as a result of a Medicaid rebate adjustment. Other revenues were lower by $193 million as a result of a payment from Takeda recognized in 2Q12. R&D expenses were up 17% in the quarter, primarily to support later-stage clinical programs, including AMG 145.